Lung Cancer Liquid Biopsy Global Market Report 2025

The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 17%. Growth during the historic period can be attributed to the increasing prevalence of smoking- and pollution-related lung disorders, expanded use of liquid biopsy for treatment monitoring, growing investment in oncology research and development, rising demand for rapid and cost-effective diagnostic solutions, and an increasing number of clinical trials.

The lung cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. Growth in the forecast period can be attributed to the rising incidence of lung cancer, increasing demand for non-invasive diagnostic methods, growing adoption of personalized medicine, heightened awareness of early cancer detection, and a rising geriatric population more vulnerable to cancer. Key trends expected during this period include advancements in circulating tumor DNA (ctDNA) analysis technologies, progress in exosome-based liquid biopsy techniques, innovations in microfluidics for isolating circulating tumor cells, the integration of AI and machine learning for biomarker interpretation, and technological breakthroughs enabling multiplex biomarker analysis.

The rising incidence of lung cancer is expected to drive the growth of the lung cancer liquid biopsy market in the coming years. Lung cancer is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs, commonly linked to smoking and environmental exposures. The increasing number of cases is primarily attributed to continued tobacco use, which exposes the lungs to carcinogens that initiate abnormal cell growth. Liquid biopsy for lung cancer enables the detection of cancer-related genetic mutations and tumor DNA through a simple blood sample, facilitating early diagnosis, personalized treatment selection, and ongoing monitoring of disease progression or therapeutic response. For example, in 2023, the American Cancer Society reported that as of January 1, 2022, 654,620 individuals in the U.S. had a history of lung cancer, with many living with metastatic disease. Approximately 80% of these patients were aged 65 or older, and 55% had been diagnosed within the past five years, reflecting low survival rates. Consequently, the growing incidence of lung cancer is significantly contributing to the expansion of the lung cancer liquid biopsy market.

Major companies in the lung cancer liquid biopsy market are prioritizing technological advancements, such as the development of blood-based lung cancer screening tests, to improve early detection, enhance diagnostic accuracy, and provide non-invasive, real-time monitoring of tumor progression and treatment response. These blood-based screening tests analyze biomarkers in the bloodstream to detect lung cancer at an early stage, offering a less invasive alternative to traditional methods. For example, in October 2023, DELFI Diagnostics Inc., a U.S.-based biotechnology company, introduced FirstLook Lung - a blood-based liquid biopsy test aimed at early lung cancer detection. This test utilizes fragmentomics to identify early-stage lung cancer with high sensitivity and a 99.8% negative predictive value. It is designed to serve as an accessible and convenient initial screening tool for individuals at risk, with the goal of improving early detection rates, boosting screening participation, and helping prioritize imaging resources for those most likely to benefit.

In February 2024, Veracyte Inc., a U.S.-based molecular diagnostics company, acquired C2i Genomics Inc. for an undisclosed amount. Through this acquisition, Veracyte seeks to strengthen its cancer diagnostics portfolio by incorporating advanced whole-genome minimal residual disease (MRD) liquid biopsy technology to improve detection and monitoring across various cancer types. C2i Genomics Inc. is a U.S.-based company specializing in cancer detection and monitoring, including liquid biopsy tests for lung cancer.

Major players in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation.

North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lung cancer liquid biopsy is a non-invasive method that examines blood or other bodily fluids to identify tumor-derived genetic material or cells. This technique supports early detection, genetic profiling, and monitoring of lung cancer by capturing cancer-specific biomarkers, providing an alternative to traditional surgical tissue biopsies.

Lung cancer liquid biopsy products include instruments, consumables kits and reagents, and software and services. Instruments refer to the hardware and analytical tools used to process and evaluate liquid biopsy samples. The technology applied includes multi-gene parallel analysis methods such as next-generation sequencing (NGS) and single-gene techniques like PCR and microarrays. Biomarkers analyzed include cell-free DNA, circulating tumor DNA, extracellular vesicles, circulating tumor cells, and other related indicators. These biomarkers are utilized for various purposes, including therapy selection, treatment monitoring, early cancer detection, recurrence surveillance, and other clinical applications. End-users include diagnostic and imaging centers, hospitals, academic and research institutions, and other relevant facilities.

The lung cancer liquid biopsy market research report is one of a series of new reports that provides lung cancer liquid biopsy market statistics, including the lung cancer liquid biopsy industry's global market size, regional shares, competitors with the lung cancer liquid biopsy market share, detailed lung cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer liquid biopsy market. This lung cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer liquid biopsy market consists of revenues earned by entities by providing services such as mutation detection and genomic profiling, treatment monitoring, and early diagnosis and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer liquid biopsy market also includes sales of NGS-based assays, CTC detection devices and others. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.